Get started
Author

Kamil Lisiecki

Observed name: K. Lisiecki
Observed institution: Molecure SA (Poland)
ORCID: 0000-0001-6757-4074
Observed ORCID: 0000-0001-6757-4074
OpenAlex ID: A5011126208
Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2023 · Bartlomiej Borek, Julita Nowicka, et al. · Molecular Cancer Therapeutics · 44
PDF
Chitinase-1 inhibition attenuates metabolic dysregulation and restores homeostasis in MASH animal models
2025 · Katarzyna Drzewicka, Katarzyna M. Głuchowska, et al. · Frontiers in Immunology · 4
PDF
717TiP An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
2023 · M.A. Dudek, Z. Zasłona, et al. · Annals of Oncology · 4
PDF
Supplementary Figure 22 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2023 · Bartlomiej Borek, Julita Nowicka, et al. · 2
Efficacy and safety of OATD-01, an oral inhibitor of chitinase-1, for treatment of active pulmonary sarcoidosis: study protocol for a randomized, double-blind, placebo-controlled, multicenter, phase 2 trial.
2024 · Theodoros Charitos, Zbigniew Zaslona, et al. · European Respiratory Journal · 1
Supplementary Figure 21 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Tables 1-11 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 1 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 15 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 17 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 16 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Materials and Methods from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 23 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 19 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 18 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 20 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figures 2 - 14 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 22 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 16 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 1 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 23 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figures 2 - 14 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Materials and Methods from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 21 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 17 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Works count: 64
Citation count: 55
H-index: 3
I10-index: 1
Year
Topic
Type